Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a hot penny stock to watch, with H.C. Wainwright analyst maintaining a Buy rating and $4.00 price target. The company’s drug candidate, sotagliflozin, shows promise for Type 1 Diabetes patients, reducing hypoglycemic events. Phase 3 trials demonstrated significant results across different patient subgroups.

Sotagliflozin has shown a notable drop in hypoglycemic events and broad applicability in Type 1 Diabetes management, bringing positive attention to Lexicon Pharmaceuticals, Inc. The drug candidate has potential for treating heart failure and neuropathic pain. Analysts believe AI stocks offer greater upside potential than LXRX.

While Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) presents investment potential, certain AI stocks may offer better returns with less risk. Consider exploring other opportunities in the AI sector for significant growth potential. This article is originally published at Insider Monkey.

Read more at Yahoo Finance: H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)